# US 2024/0189218 A1 · Compositions and methods for improving mitochondrial function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189218 A1
- Document ID: US20240189218A1
- Status: Published application
- Kind: A1
- Application number: 18/282,719
- Filed: 2022-03-18
- Published: 2024-06-13
- Earliest claimed: 2021-03-18
- Assignees: Yuva Biosciences, Inc.
- Applicants: Yuva Biosciences, Inc.
- Inventors: Keshav K. Singh; Leopoldo Aguilera Aguirre; Greg Schmergel
- Web page: https://patentgrep.com/patent/US20240189218A1

## CPC

- A61K 8/9789: Magnoliopsida [dicotyledons]
- A61K 36/47: Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
- A61K 8/11: Encapsulated compositions
- A61K 8/365: Hydroxycarboxylic acids; Ketocarboxylic acids
- A61K 8/368: with carboxyl groups directly bound to carbon atoms of aromatic rings
- A61K 8/375: {the alcohol moiety containing more than one hydroxy group}
- A61K 8/4973: {with oxygen as the only hetero atom}
- A61K 8/498: {having 6-membered rings or their condensed derivatives, e.g. coumarin}
- A61K 8/602: {Glycosides, e.g. rutin}
- A61K 8/9711: Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
- A61K 36/03: Phaeophycota or phaeophyta (brown algae), e.g. Fucus
- A61K 36/185: Magnoliopsida (dicotyledons)
- A61Q 5/02: Preparations for cleaning the hair
- A61Q 5/10: Preparations for permanently dyeing the hair
- A61Q 7/00: Preparations for affecting hair growth
- A61Q 19/00: Preparations for care of the skin
- A61Q 19/008: {Preparations for oily skin}
- A61Q 19/02: for chemically bleaching or whitening the skin
- A61Q 19/08: Anti-ageing preparations
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

Methods for treating or preventing mitochondrial dysfunction are disclosed. Methods for treating or preventing a disease or condition associated with mitochondrial dysfunction or a symptom thereof are disclosed. Methods for treating or preventing an aging-associated chronic disease or condition related to mitochondrial dysfunction or a symptom thereof are disclosed. Methods for improving or preventing a decrease in energy level and/or vitality are disclosed. The methods include administering an emblica extract or a compound constituent of an emblica extract, or fucus extract or a compound constituent of a fucus extract, or a chebula extract or a compound constituent of a chebula extract.

## Claims

### Claim at position 1

-62. (canceled)

### Claim 63

A preparation comprising a treatment agent selected from an isolated compound constituent of emblica extract, chebula extract, or a metabolite thereof, a compound having a similarity score of at least 95% with the isolated compound constituent of emblica extract, chebula extract, or metabolite thereof, a pharmaceutically acceptable form thereof, or a combination thereof in a pharmaceutically or cosmetically acceptable vehicle.

### Claim 64 (depends on 63)

The preparation of claim 63, wherein the treatment agent comprises an isolated ellagitannin.

### Claim 65 (depends on 63)

The preparation of claim 63, wherein the treatment agent is isolated emblicanin A, isolated emblicanin B, isolated chebulinic acid, isolated chebulagic acid, isolated gallic acid, isolated kaempferol, isolated punicalagin, or a combination thereof.

### Claim 66 (depends on 63)

The preparation of claim 63, wherein the treatment agent is derived from, purified from, or isolated from an extract.

### Claim 67 (depends on 66)

The preparation of claim 66, wherein the extract is an extract of Emblica officinalis, Terminilia chebula, Terminalia arborea, or Lumnitzera racemose.

### Claim 68 (depends on 63)

The preparation of claim 63, wherein the treatment agent is synthetic.

### Claim 69 (depends on 63)

The preparation of claim 63, wherein the treatment agent is formulated in a nanoparticle-based delivery carrier.

### Claim 70 (depends on 69)

The preparation of claim 69, wherein the nanoparticle-based delivery carrier has an average size of about 10 to 5000 nm.

### Claim 71 (depends on 69)

The preparation of claim 69, wherein the nanoparticle-based delivery carrier comprises and/or is functionalized with a carbon-based nanomaterial, liposomal delivery vehicle, polymeric nanocarrier, micelle, dendrimer, lipophilic cation, solid-lipid nanoparticle (SLN), peptide-based nanomaterial, nanostructured lipid carrier (NLC), niosome, nanoemulsion, metal nanoparticle, nanosphere, polymerosome, cubosome, or a combination thereof.

### Claim 72 (depends on 69)

The preparation of claim 69, wherein the nanoparticle-based delivery carrier is functionalized with a mitochondrial targeting agent.

### Claim 73 (depends on 72)

The preparation of claim 72, wherein the mitochondrial targeting agent is selected from a mitochondrial targeting antibody, a polymeric functional moiety (e.g., polyethylene glycol (PEG)), a lipophilic cation (e.g., triphenylphosphine (TPP)), a mitochondrial targeting peptide (MPP), a derivative thereof, or a combination thereof.

### Claim 74 (depends on 69)

The preparation of claim 69, wherein the treatment agent is conjugated to a mitochondrial targeting agent.

### Claim 75 (depends on 74)

The preparation of claim 74, wherein the mitochondrial targeting agent is selected from a mitochondrial targeting antibody, a polymeric functional moiety (e.g., polyethylene glycol (PEG)), a lipophilic cation (e.g., triphenylphosphine (TPP)), a mitochondrial targeting peptide (MPP), a derivative thereof, or a combination thereof.

### Claim 76 (depends on 63)

The preparation of claim 63, formulated for topical administration to the subject.

### Claim 77 (depends on 76)

The preparation of claim 76, formulated as a topical solution, oil, cream, emulsion, foam, or gel.

### Claim 78 (depends on 77)

The preparation of claim 77, formulated as a shampoo, conditioner, spray, cream, foam, gel, balm, body wash, soap, lotion, or make-up.

### Claim 79 (depends on 63)

The preparation of claim 63, formulated for parenteral administration to the subject.

### Claim 80 (depends on 79)

The preparation of claim 79, formulated as a parenteral liquid solution.

### Claim 81 (depends on 63)

The preparation of claim 63, formulated for enteral administration to the subject.

### Claim 82 (depends on 81)

The preparation of claim 81, formulated as an enteral capsule or tablet, or dietary supplement or food, e.g., food, food supplement, medical food, food additive, nutraceutical, or drink.

### Claim 83 (depends on 63)

The preparation of claim 63, wherein the treatment agent is purified, e.g., at least 80% purified, at least 85% purified, at least 90% purified, at least 95% purified, at least 98% purified, at least 99% purified, at least 99.9% purified, at least 99.99% purified, or at least 99.999% purified.

### Claim 84 (depends on 63)

The preparation of claim 63, formulated for immediate release.

### Claim 85 (depends on 63)

The preparation of claim 63, formulated for extended release, e.g., controlled or sustained release.

### Claim 86 (depends on 63)

The preparation of claim 63, comprising a skin penetration enhancer, e.g., a chemical skin penetration enhancer or a physical skin penetration enhancer.

### Claim 87 (depends on 86)

The preparation of claim 86, wherein the chemical skin penetration enhancer comprises niosomes, proniosomes, liposomes, phospholipids, glycerin, alcohols, e.g., ethanol or glycol, sulfoxides, e.g., dimethyl sulfoxide, laurocapram, pyrrolidones, dimethyl isosorbide, isopropyl myristate, propylene glycol, oleic acid, eucalyptol, water/aqua (hydration), surfactants, urea, fatty acids, fatty alcohols, and terpenes or terpenoids, or a combination thereof.

### Claim 88 (depends on 86)

The preparation of claim 86, wherein the physical skin penetration enhancer comprises a roller, scraper, scrubber, exfoliator, microdermabrasion needles, iontophoresis device, electroporation device, ultrasound device, e.g., sonophoresis device, thermal ablation, magnetophoresis, photomechanical waves, electron beam irradiation, low light therapy device, e.g., a light emitting diode (LED) source, or a combination thereof.

### Claim 89 (depends on 63)

The preparation of claim 63, wherein the treatment agent is formulated for administration in combination with caffeine, a B vitamin, e.g., B1, B2, B3, B5, B6, B8, B9 and/or B12 vitamin, vitamin C, iron, magnesium, zinc, a UV-blocking agent, moisturizer, sunscreen, wrinkle cream, retinoid, alpha-hydroxy acid, beta-hydroxy acid, squalene, antioxidant, e.g., CoQ10, vitamin E, carotenoid, e.g., beta-carotene, mineral, e.g., selenium or manganese, glutathione, lipoic acid, flavonoid, betaflavonoid, phenol, polyphenol, phytoestrogen, mitoquinol mesylate, ubiquinone, tretinoin, glycosaminoglycan (GAG), lactic acid, malic acid, citric acid, tartaric acid, hydroquinone, kojic acid, L-ascorbic acid, licorice extract, N-acetylglucosamine, niacinamide, soy, dermal filler or injection, e.g. hyaluronic acid or calcium hydroxylapatite, botulinum toxin, laser resurfacing procedure, ultrasound therapy, chemical peel, e.g., glycolic acid peel, trichloroacetic acid or salicylic acid, dermabrasion procedure, or combination thereof.

### Claim 90 (depends on 89)

The preparation of claim 89, wherein the treatment agent is formulated for administration in combination with a second agent approved to treat or commonly used to treat a target disease or condition or a symptom thereof.

### Claim 91 (depends on 90)

The preparation of claim 90, wherein the target disease or condition or symptom thereof is associated with mitochondrial dysfunction, an inflammatory response, or inflammation.

### Claim 92 (depends on 63)

The preparation of claim 63, formulated to have a concentration of 0.01% to 2% of the compound.

### Claim 93 (depends on 63)

The preparation of claim 63, comprising an emblica extract, a chebula extract, or a fucus extract fortified with the treatment agent.

### Claim 94

A method of treating or preventing a disease or condition associated with mitochondrial dysfunction in a subject, the method comprising administering to the subject a preparation comprising an effective amount of an emblica extract, a chebula extract, a treatment agent comprising an isolated compound constituent of emblica extract, chebula extract, or a metabolite thereof, a compound having a similarity score of at least 95% with the isolated compound constituent of emblica extract, chebula extract, or metabolite thereof, a pharmaceutically acceptable form thereof, or a combination thereof.

### Claim 95 (depends on 94)

The method of claim 94, wherein the disease or condition associated with mitochondrial dysfunction is a cardiovascular disease, diabetes, cancer, neurological disorder, skin disease or condition, hair or scalp disease or condition, or symptom thereof.

### Claim 96 (depends on 94)

The method of claim 94, wherein the disease or condition associated with mitochondrial dysfunction is aging, an aging-associated chronic disease or condition, reduced energy levels and vitality, or symptom thereof.

### Claim 97 (depends on 94)

The method of claim 94, wherein the effective amount is a therapeutically effective amount.

### Claim 98 (depends on 94)

The method of claim 94, wherein the effective amount is sufficient to induce mitochondrial biogenesis.

### Claim 99 (depends on 94)

The method of claim 94, wherein the treatment or prevention involves inducing mitochondrial biogenesis and/or improving mitochondrial function.

### Claim 100 (depends on 94)

The method of claim 94, wherein administration increases expression of at least one protein selected from PGC-1a, TFAM, NRF-1, and COX II.

### Claim 101 (depends on 94)

The method of claim 94, wherein administration activates a gene associated with mitochondrial activity.

### Claim 102 (depends on 94)

The method of claim 94, wherein administration alters, e.g., decreases expression of at least one gene selected from the group consisting of: NF-κB, COX-2, INF-β1, CCL5, MMP1, MMP2, MMP9, MMP13, IGF1R, VEGF, and MRPS5, alters, e.g., increases expression of at least one gene selected from the group consisting of: TIMP1, KLOTHO, COL1A1, MTCO2, TFAM, and VDAC, or activates a gene selected from: FGF2, FGFR1, COX7A1, PDK4, FAM173A, MRPL12, and WNT11.

### Claim 103 (depends on 94)

The method of claim 94, wherein the preparation is administered topically.

### Claim 104 (depends on 103)

The method of claim 103, wherein the preparation is formulated as a topical solution, oil, cream, emulsion, foam, or gel.

### Claim 105 (depends on 103)

The method of claim 103, wherein the preparation is formulated as a shampoo, conditioner, spray, cream, foam, gel, balm, body wash, soap, lotion, or make-up.

### Claim 106 (depends on 94)

The method of claim 94, wherein the preparation is administered parenterally.

### Claim 107 (depends on 94)

The method of claim 94, wherein the preparation is administered enterally.

### Claim 108 (depends on 94)

The method of claim 94, wherein the preparation is administered locally.

### Claim 109 (depends on 94)

The method of claim 94, wherein the preparation is administered systemically.

### Claim 110 (depends on 94)

The method of claim 94, wherein the treatment agent is formulated in a nanoparticle-based delivery carrier or conjugated to a nanoparticle-based delivery carrier.

### Claim 111 (depends on 110)

The preparation of claim 110, wherein the nanoparticle-based delivery carrier has an average size of about 10 to 5000 nm.

### Claim 112 (depends on 110)

The preparation of claim 110, wherein the nanoparticle-based delivery carrier comprises and/or is functionalized with a carbon-based nanomaterial, liposomal delivery vehicle, polymeric nanocarrier, micelle, dendrimer, lipophilic cation, solid-lipid nanoparticle (SLN), peptide-based nanomaterial, nanostructured lipid carrier (NLC), niosome, nanoemulsion, metal nanoparticle, nanosphere, polymerosome, cubosome, or a combination thereof.

### Claim 113 (depends on 110)

The method of claim 110, wherein the nanoparticle-based delivery carrier is functionalized with a mitochondrial targeting agent.

### Claim 114 (depends on 113)

The preparation of claim 113, wherein the mitochondrial targeting agent is selected from a mitochondrial targeting antibody, a polymeric functional moiety (e.g., polyethylene glycol (PEG)), a lipophilic cation (e.g., triphenylphosphine (TPP)), a mitochondrial targeting peptide (MPP), a derivative thereof, or a combination thereof.

### Claim 115 (depends on 94)

The method of claim 94, wherein the preparation is administered in combination with a skin penetration enhancer, e.g., a chemical skin penetration enhancer or a physical skin penetration enhancer.

### Claim 116 (depends on 115)

The method of claim 115, wherein the chemical skin penetration enhancer comprises niosomes, proniosomes, liposomes, phospholipids, glycerin, alcohols, e.g., ethanol or glycol, sulfoxides, e.g., dimethyl sulfoxide, laurocapram, pyrrolidones, dimethyl isosorbide, isopropyl myristate, propylene glycol, oleic acid, eucalyptol, water/aqua (hydration), surfactants, urea, fatty acids, fatty alcohols, and terpenes or terpenoids, or a combination thereof.

### Claim 117 (depends on 115)

The method of claim 115, wherein the physical skin penetration enhancer comprises a roller, scraper, scrubber, exfoliator, microdermabrasion needles, iontophoresis device, electroporation device, ultrasound device, e.g., sonophoresis device, thermal ablation, magnetophoresis, photomechanical waves, electron beam irradiation, low light therapy device, e.g., a light emitting diode (LED) source, or a combination thereof.

### Claim 118 (depends on 94)

The method of claim 94, further comprising administering to the subject a second or subsequent amount of the preparation.

### Claim 119 (depends on 118)

The method of claim 118, wherein the second or subsequent amount is administered as a second dose of the same formulation.

### Claim 120 (depends on 118)

The method of claim 118, wherein the second or subsequent amount is administered in another formulation.

### Claim 121 (depends on 94)

The method of claim 94, comprising administering the preparation to the subject in combination with caffeine, a B vitamin, e.g., B1, B2, B3, B5, B6, B8, B9 and/or B12 vitamin, vitamin C, iron, magnesium, zinc, a UV-blocking agent, moisturizer, sunscreen, wrinkle cream, retinoid, alpha-hydroxy acid, beta-hydroxy acid, squalene, antioxidant, e.g., CoQ10, vitamin E, carotenoid, e.g., beta-carotene, mineral, e.g., selenium or manganese, glutathione, lipoic acid, flavonoid, betaflavonoid, phenol, polyphenol, phytoestrogen, mitoquinol mesylate, ubiquinone, tretinoin, glycosaminoglycan (GAG), lactic acid, malic acid, citric acid, tartaric acid, hydroquinone, kojic acid, L-ascorbic acid, licorice extract, N-acetylglucosamine, niacinamide, squalene, soy, dermal filler or injection, e.g. hyaluronic acid or calcium hydroxylapatite, botulinum toxin, laser resurfacing procedure, ultrasound therapy, chemical peel, e.g., glycolic acid peel, trichloroacetic acid or salicylic acid, dermabrasion procedure, or a combination thereof.

### Claim 122 (depends on 94)

The preparation of claim 94, comprising administering the preparation to the subject in combination with a second agent approved to treat or commonly used to treat mitochondrial dysfunction, an inflammatory response, or inflammation.

### Claim 123

A method of treating or preventing a skin disease or condition in a subject, the method comprising administering to the subject a preparation comprising an effective amount of an emblica extract, a chebula extract, a treatment agent comprising an isolated compound constituent of emblica extract, chebula extract, or a metabolite thereof, a compound having a similarity score of at least 95% with the isolated compound constituent of emblica extract, chebula extract, or metabolite thereof, a pharmaceutically acceptable form thereof, or a combination thereof.

### Claim 124 (depends on 123)

The method of claim 123, wherein the skin disease or condition is a characteristic of skin aging, skin wrinkles, change in skin pigmentation, senile lentigines, or a disease or condition of sebaceous glands.

### Claim 125 (depends on 123)

The method of claim 123, wherein administration promotes firmness, hydration, elasticity, radiance, tone evenness, visual smoothness, or tactile smoothness of skin of the subject.

### Claim 126 (depends on 123)

The method of claim 123, wherein the effective amount is a therapeutically effective amount.

### Claim 127 (depends on 123)

The method of claim 123, wherein the effective amount is sufficient to induce mitochondrial biogenesis.

### Claim 128 (depends on 123)

The method of claim 123, wherein the treatment or prevention involves inducing mitochondrial biogenesis and/or improving mitochondrial function.

### Claim 129 (depends on 123)

The method of claim 123, wherein administration increases expression of at least one protein selected from PGC-1a, TFAM, NRF-1, and COX II.

### Claim 130 (depends on 123)

The method of claim 123, wherein administration activates a gene associated with mitochondrial activity.

### Claim 131 (depends on 123)

The method of claim 123, wherein administration alters, e.g., decreases expression of at least one gene selected from the group consisting of: NF-κB, COX-2, INF-β1, CCL5, MMP1, MMP2, MMP9, MMP13, IGF1R, VEGF, and MRPS5, alters, e.g., increases expression of at least one gene selected from the group consisting of: TIMP1, KLOTHO, COL1A1, MTCO2, TFAM, and VDAC, or activates a gene selected from: FGF2, FGFR1, COX7A1, PDK4, FAM173A, MRPL12, and WNT11.

### Claim 132 (depends on 123)

The method of claim 123, wherein the preparation is administered topically.

### Claim 133 (depends on 132)

The method of claim 132, wherein the preparation is formulated as a topical solution, oil, cream, emulsion, foam, or gel.

### Claim 134 (depends on 132)

The method of claim 132, wherein the preparation is formulated as a shampoo, conditioner, spray, cream, foam, gel, balm, body wash, soap, lotion, or make-up.

### Claim 135 (depends on 123)

The method of claim 123, wherein the preparation is administered parenterally.

### Claim 136 (depends on 123)

The method of claim 123, wherein the preparation is administered enterally.

### Claim 137 (depends on 123)

The method of claim 123, wherein the preparation is administered locally.

### Claim 138 (depends on 123)

The method of claim 123, wherein the preparation is administered systemically.

### Claim 139 (depends on 123)

The method of claim 123, wherein the treatment agent is formulated in a nanoparticle-based delivery carrier or conjugated to a nanoparticle-based delivery carrier.

### Claim 140 (depends on 139)

The preparation of claim 139, wherein the nanoparticle-based delivery carrier has an average size of about 10 to 5000 nm.

### Claim 141 (depends on 139)

The preparation of claim 139, wherein the nanoparticle-based delivery carrier comprises and/or is functionalized with a carbon-based nanomaterial, liposomal delivery vehicle, polymeric nanocarrier, micelle, dendrimer, lipophilic cation, solid-lipid nanoparticle (SLN), peptide-based nanomaterial, nanostructured lipid carrier (NLC), niosome, nanoemulsion, metal nanoparticle, nanosphere, polymerosome, cubosome, or a combination thereof.

### Claim 142 (depends on 139)

The method of claim 139, wherein the nanoparticle-based delivery carrier is functionalized with a mitochondrial targeting agent.

### Claim 143 (depends on 142)

The preparation of claim 142, wherein the mitochondrial targeting agent is selected from a mitochondrial targeting antibody, a polymeric functional moiety (e.g., polyethylene glycol (PEG)), a lipophilic cation (e.g., triphenylphosphine (TPP)), a mitochondrial targeting peptide (MPP), a derivative thereof, or a combination thereof.

### Claim 144 (depends on 123)

The method of claim 123, wherein the preparation is administered in combination with a skin penetration enhancer, e.g., a chemical skin penetration enhancer or a physical skin penetration enhancer.

### Claim 145 (depends on 144)

The method of claim 144, wherein the chemical skin penetration enhancer comprises niosomes, proniosomes, liposomes, phospholipids, glycerin, alcohols, e.g., ethanol or glycol, sulfoxides, e.g., dimethyl sulfoxide, laurocapram, pyrrolidones, dimethyl isosorbide, isopropyl myristate, propylene glycol, oleic acid, eucalyptol, water/aqua (hydration), surfactants, urea, fatty acids, fatty alcohols, and terpenes or terpenoids, or a combination thereof.

### Claim 146 (depends on 144)

The method of claim 144, wherein the physical skin penetration enhancer comprises a roller, scraper, scrubber, exfoliator, microdermabrasion needles, iontophoresis device, electroporation device, ultrasound device, e.g., sonophoresis device, thermal ablation, magnetophoresis, photomechanical waves, electron beam irradiation, low light therapy device, e.g., a light emitting diode (LED) source, or a combination thereof.

### Claim 147 (depends on 123)

The method of claim 123, further comprising administering to the subject a second or subsequent amount of the preparation.

### Claim 148 (depends on 147)

The method of claim 147, wherein the second or subsequent amount is administered as a second dose of the same formulation.

### Claim 149 (depends on 147)

The method of claim 147, wherein the second or subsequent amount is administered in another formulation.

### Claim 150 (depends on 123)

The method of claim 123, comprising administering the preparation to the subject in combination with caffeine, a B vitamin, e.g., B1, B2, B3, B5, B6, B8, B9 and/or B12 vitamin, vitamin C, iron, magnesium, zinc, a UV-blocking agent, moisturizer, sunscreen, wrinkle cream, retinoid, alpha-hydroxy acid, beta-hydroxy acid, squalene, antioxidant, e.g., CoQ10, vitamin E, carotenoid, e.g., beta-carotene, mineral, e.g., selenium or manganese, glutathione, lipoic acid, flavonoid, betaflavonoid, phenol, polyphenol, phytoestrogen, mitoquinol mesylate, ubiquinone, tretinoin, glycosaminoglycan (GAG), lactic acid, malic acid, citric acid, tartaric acid, hydroquinone, kojic acid, L-ascorbic acid, licorice extract, N-acetylglucosamine, niacinamide, squalene, soy, dermal filler or injection, e.g. hyaluronic acid or calcium hydroxylapatite, botulinum toxin, laser resurfacing procedure, ultrasound therapy, chemical peel, e.g., glycolic acid peel, trichloroacetic acid or salicylic acid, dermabrasion procedure, or a combination thereof.

### Claim 151 (depends on 123)

The preparation of claim 123, comprising administering the preparation to the subject in combination with a second agent approved to treat or commonly used to treat the skin disease or condition, mitochondrial dysfunction, an inflammatory response, or inflammation.

### Claim 152

A method of treating or preventing a scalp or hair disease or condition in a subject, the method comprising administering to the subject a preparation comprising an effective amount of an emblica extract, a chebula extract, a treatment agent comprising an isolated compound constituent of emblica extract, chebula extract, or a metabolite thereof, a compound having a similarity score of at least 95% with the isolated compound constituent of emblica extract, chebula extract, or metabolite thereof, a pharmaceutically acceptable form thereof, or a combination thereof.

### Claim 153 (depends on 152)

The method of claim 152, wherein the scalp or hair disease or condition is hair loss, hair thinning, or change in hair pigmentation.

### Claim 154 (depends on 153)

The method of claim 153, wherein the hair loss comprises total alopecia, partial alopecia, or male or female pattern baldness.

### Claim 155 (depends on 153)

The method of claim 153, wherein the hair loss is a genetic condition or associated with an autoimmune disease, an environmental factor, or a course of treatment.

### Claim 156 (depends on 152)

The method of claim 152, wherein the effective amount is a therapeutically effective amount.

### Claim 157 (depends on 152)

The method of claim 152, wherein the effective amount is sufficient to induce mitochondrial biogenesis.

### Claim 158 (depends on 152)

The method of claim 152, wherein the treatment or prevention involves inducing mitochondrial biogenesis and/or improving mitochondrial function.

### Claim 159 (depends on 152)

The method of claim 152, wherein administration increases expression of at least one protein selected from PGC-1a, TFAM, NRF-1, and COX II.

### Claim 160 (depends on 152)

The method of claim 152, wherein administration activates a gene associated with mitochondrial activity.

### Claim 161 (depends on 152)

The method of claim 152, wherein administration alters, e.g., decreases expression of at least one gene selected from the group consisting of: NF-κB, COX-2, INF-β1, CCL5, MMP1, MMP2, MMP9, MMP13, IGF1R, VEGF, and MRPS5, alters, e.g., increases expression of at least one gene selected from the group consisting of: TIMP1, KLOTHO, COL1A1, MTCO2, TFAM, and VDAC, or activates a gene selected from: FGF2, FGFR1, COX7A1, PDK4, FAM173A, MRPL12, and WNT11.

### Claim 162 (depends on 152)

The method of claim 152, wherein the preparation is administered topically.

### Claim 163 (depends on 162)

The method of claim 162, wherein the preparation is formulated as a topical solution, oil, cream, emulsion, foam, or gel.

### Claim 164 (depends on 162)

The method of claim 162, wherein the preparation is formulated as a shampoo, conditioner, spray, cream, foam, gel, balm, body wash, soap, lotion, or make-up.

### Claim 165 (depends on 152)

The method of claim 152, wherein the preparation is administered parenterally.

### Claim 166 (depends on 152)

The method of claim 152, wherein the preparation is administered enterally.

### Claim 167 (depends on 152)

The method of claim 152, wherein the preparation is administered locally.

### Claim 168 (depends on 152)

The method of claim 152, wherein the preparation is administered systemically.

### Claim 169 (depends on 152)

The method of claim 152, wherein the treatment agent is formulated in a nanoparticle-based delivery carrier or conjugated to a nanoparticle-based delivery carrier.

### Claim 170 (depends on 169)

The preparation of claim 169, wherein the nanoparticle-based delivery carrier has an average size of about 10 to 5000 nm.

### Claim 171 (depends on 169)

The preparation of claim 169, wherein the nanoparticle-based delivery carrier comprises and/or is functionalized with a carbon-based nanomaterial, liposomal delivery vehicle, polymeric nanocarrier, micelle, dendrimer, lipophilic cation, solid-lipid nanoparticle (SLN), peptide-based nanomaterial, nanostructured lipid carrier (NLC), niosome, nanoemulsion, metal nanoparticle, nanosphere, polymerosome, cubosome, or a combination thereof.

### Claim 172 (depends on 169)

The method of claim 169, wherein the nanoparticle-based delivery carrier is functionalized with a mitochondrial targeting agent.

### Claim 173 (depends on 172)

The preparation of claim 172, wherein the mitochondrial targeting agent is selected from a mitochondrial targeting antibody, a polymeric functional moiety (e.g., polyethylene glycol (PEG)), a lipophilic cation (e.g., triphenylphosphine (TPP)), a mitochondrial targeting peptide (MPP), a derivative thereof, or a combination thereof.

### Claim 174 (depends on 152)

The method of claim 152, wherein the preparation is administered in combination with a skin penetration enhancer, e.g., a chemical skin penetration enhancer or a physical skin penetration enhancer.

### Claim 175 (depends on 174)

The method of claim 174, wherein the chemical skin penetration enhancer comprises niosomes, proniosomes, liposomes, phospholipids, glycerin, alcohols, e.g., ethanol or glycol, sulfoxides, e.g., dimethyl sulfoxide, laurocapram, pyrrolidones, dimethyl isosorbide, isopropyl myristate, propylene glycol, oleic acid, eucalyptol, water/aqua (hydration), surfactants, urea, fatty acids, fatty alcohols, and terpenes or terpenoids, or a combination thereof.

### Claim 176 (depends on 174)

The method of claim 174, wherein the physical skin penetration enhancer comprises a roller, scraper, scrubber, exfoliator, microdermabrasion needles, iontophoresis device, electroporation device, ultrasound device, e.g., sonophoresis device, thermal ablation, magnetophoresis, photomechanical waves, electron beam irradiation, low light therapy device, e.g., a light emitting diode (LED) source, or a combination thereof.

### Claim 177 (depends on 152)

The method of claim 152, further comprising administering to the subject a second or subsequent amount of the preparation.

### Claim 178 (depends on 177)

The method of claim 177, wherein the second or subsequent amount is administered as a second dose of the same formulation.

### Claim 179 (depends on 177)

The method of claim 177, wherein the second or subsequent amount is administered in another formulation.

### Claim 180 (depends on 152)

The method of claim 152, comprising administering the preparation to the subject in combination with caffeine, a B vitamin, e.g., B1, B2, B3, B5, B6, B8, B9 and/or B12 vitamin, vitamin C, iron, magnesium, zinc, a UV-blocking agent, moisturizer, sunscreen, wrinkle cream, retinoid, alpha-hydroxy acid, beta-hydroxy acid, squalene, antioxidant, e.g., CoQ10, vitamin E, carotenoid, e.g., beta-carotene, mineral, e.g., selenium or manganese, glutathione, lipoic acid, flavonoid, betaflavonoid, phenol, polyphenol, phytoestrogen, mitoquinol mesylate, ubiquinone, tretinoin, glycosaminoglycan (GAG), lactic acid, malic acid, citric acid, tartaric acid, hydroquinone, kojic acid, L-ascorbic acid, licorice extract, N-acetylglucosamine, niacinamide, squalene, soy, dermal filler or injection, e.g. hyaluronic acid or calcium hydroxylapatite, botulinum toxin, laser resurfacing procedure, ultrasound therapy, chemical peel, e.g., glycolic acid peel, trichloroacetic acid or salicylic acid, dermabrasion procedure, or a combination thereof.

### Claim 181 (depends on 152)

The preparation of claim 152, comprising administering the preparation to the subject in combination with a second agent approved to treat or commonly used to treat the scalp or hair disease or condition, mitochondrial dysfunction, an inflammatory response, or inflammation.
